The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke

Exclusion Criteria12

• Hemorrhagic stroke or hemorrhagic transformation of ischemic focus, traumatic brain injuries
• Vertebrobasilar stroke and/or development of acute insufficiency syndromes in the arteries of the vertebrobasilar system
• A patient with ischemic stroke who is a candidate for reperfusion therapy or who has undergone reperfusion therapy before participation in this study.
• The presence of anatomical abnormalities of the cerebral vessels (arteriovenous malformations, cavernous malformations, aneurysms, atresia of at least one of the extracranial arteries) according to the anamnesis or CT/MRI data.
• Progression of neurological symptoms of stroke, defined as an increase in the NIHSS score by 4 points at the second assessment (immediately before randomization) from the value obtained at the first assessment (immediately after signing the informed consent form).
• Surgery on the carotid arteries less than 1 year before screening.
• History of stroke less than 1 year before screening.
• Myocardial infarction less than 6 months before screening.
• Chronic renal failure stage 2-3 (creatinine clearance less than 40 ml/min).
• Pregnancy or lactation.
• Participation in another trial within 28 days prior to enrollment.
• Use of prohibited medications.